Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds ...

Donald Trump's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...

The company plans to allocate a record amount to capital expenditures to build artificial-intelligence infrastructure. The company expects bookings of between $5.55 billion to $5.65 billion for the ...

Health-care companies rose after strong earnings from one obesity-drug maker. Eli Lilly shares rose after it reiterated its forecast for 32% 2025 revenue growth, amid rising demand for its Zepbound ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

NEW YORK/SINGAPORE (Reuters) -Asia shares rose on Thursday, tracking gains on Wall Street following a see-saw session, while ...

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

A product data company sues metalworking products manufacturer for allegedly using confidential information to "knock-off" ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.